NASDAQ:MREO Mereo BioPharma Group (MREO) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free MREO Stock Alerts $3.08 -0.19 (-5.81%) (As of 12:29 PM ET) Add Compare Share Share Today's Range$3.08▼$3.3350-Day Range$2.58▼$3.9752-Week Range$0.92▼$4.36Volume586,450 shsAverage Volume1.49 million shsMarket Capitalization$384.96 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Mereo BioPharma Group alerts: Email Address Mereo BioPharma Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside102.5% Upside$6.50 Price TargetShort InterestHealthy2.26% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.16 out of 5 starsMedical Sector681st out of 915 stocksPharmaceutical Preparations Industry318th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingMereo BioPharma Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMereo BioPharma Group has only been the subject of 2 research reports in the past 90 days.Read more about Mereo BioPharma Group's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.26% of the outstanding shares of Mereo BioPharma Group have been sold short.Short Interest Ratio / Days to CoverMereo BioPharma Group has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mereo BioPharma Group has recently increased by 2.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMereo BioPharma Group does not currently pay a dividend.Dividend GrowthMereo BioPharma Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MREO. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 5 people have searched for MREO on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Mereo BioPharma Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mereo BioPharma Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.13% of the stock of Mereo BioPharma Group is held by insiders.Percentage Held by Institutions62.83% of the stock of Mereo BioPharma Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mereo BioPharma Group's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioMereo BioPharma Group has a P/B Ratio of 8.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mereo BioPharma Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Mereo BioPharma Group Stock (NASDAQ:MREO)Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Read More MREO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MREO Stock News HeadlinesMay 1, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday TradingMay 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Mereo Biopharma Group Plc (MREO) and Arcus Biosciences (RCUS)May 10, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.May 1, 2024 | markets.businessinsider.comStrong Buy Rating for Mereo Biopharma on Setrusumab’s Promising Phase 3 Progress and Financial OutlookApril 3, 2024 | globenewswire.comMereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 27, 2024 | globenewswire.comMereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 16, 2024 | finance.yahoo.comMREO Apr 2024 3.500 putMarch 16, 2024 | ca.finance.yahoo.comMREO Aug 2024 5.500 callMay 10, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 16, 2024 | finance.yahoo.comMREO Apr 2024 1.500 callMarch 16, 2024 | finance.yahoo.comMREO Apr 2024 3.000 putMarch 13, 2024 | seekingalpha.comVoyager Therapeutics gets new chief medical officerMarch 5, 2024 | globenewswire.comMereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma ConferenceFebruary 23, 2024 | finance.yahoo.comMereo BioPharma Group plc (MREO)January 31, 2024 | finance.yahoo.comAM Best Assigns Preliminary Credit Assessment to Mereo Insurance LimitedJanuary 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shockwave Medical (SWAV), Amarin (AMRN) and Mereo Biopharma Group Plc (MREO)December 20, 2023 | benzinga.comMereo BioPharma Group Stock (NASDAQ:MREO) Dividends: History, Yield and DatesDecember 19, 2023 | finance.yahoo.comHedge Funds Say These Penny Stocks Are Poised to ExplodeNovember 3, 2023 | finance.yahoo.comUltragenyx (RARE) Q3 Earnings and Revenues Miss EstimatesOctober 25, 2023 | finanznachrichten.deMereo BioPharma Group plc: Mereo BioPharma Reports on Recent Program Developments and Provides Financial UpdateOctober 25, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO)October 16, 2023 | benzinga.comWhy Is Mereo BioPharma Stock Trading Higher Today?October 14, 2023 | finance.yahoo.comUltragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)September 27, 2023 | finance.yahoo.comMREO Oct 2023 2.500 putSeptember 9, 2023 | msn.comCantor Fitzgerald Reiterates Mereo Biopharma Group Plc - ADR (MREO) Overweight RecommendationSeptember 7, 2023 | finance.yahoo.comMereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate UpdateAugust 19, 2023 | fool.comMereo BioPharma Group Plc (NASDAQ: MREO)See More Headlines Receive MREO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/07/2023Today5/10/2024Next Earnings (Estimated)6/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MREO CUSIPN/A CIK1719714 Webwww.mereobiopharma.com Phone44-33-3023-7300FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Target$6.50 High Stock Price Target$7.00 Low Stock Price Target$6.00 Potential Upside/Downside+98.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.09 Current Ratio6.72 Quick Ratio6.72 Sales & Book Value Annual Sales$10 million Price / Sales40.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book8.18Miscellaneous Outstanding Shares124,986,000Free Float119,824,000Market Cap$408.70 million OptionableOptionable Beta0.88 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Denise Vera Scots-Knight Ph.D. (Age 65)Co-Founder, CEO & Executive Director Comp: $890.56kMr. Charles Edward Sermon (Age 55)Co-Founder, General Counsel, Business Development & Company Secretary Comp: $625.79kMs. Christine Fox CPA (Age 43)Chief Financial Officer Comp: $569.77kDr. John P. Richard M.B.A. (Age 67)Co-Founder & Chief Business Officer Dr. John A. Lewicki Ph.D. (Age 72)Chief Scientific Officer Dr. Jackie Parkin (Age 66)Senior VP & Therapeutic Head Ms. Alexandra Hughes-Wilson (Age 53)Chief of Patient Access & Commercial Planning Dr. Suba Krishnan (Age 59)Senior Vice President of Clinical Development Mr. Bo KaraSenior VP and Head of Pharmaceutical Development & CMCMore ExecutivesKey CompetitorsErascaNASDAQ:ERASRani TherapeuticsNASDAQ:RANITerns PharmaceuticalsNASDAQ:TERNHarrowNASDAQ:HROWNature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInstitutional OwnershipMonaco Asset Management SAMSold 271,494 shares on 5/9/2024Ownership: 0.324%Advisors Preferred LLCBought 8,262 shares on 5/8/2024Ownership: 0.007%SG Americas Securities LLCBought 16,221 shares on 5/7/2024Ownership: 0.013%BNP Paribas Financial MarketsBought 17,432 shares on 5/1/2024Ownership: 0.014%Forefront Analytics LLCSold 29,525 shares on 2/15/2024Ownership: 0.029%View All Institutional Transactions MREO Stock Analysis - Frequently Asked Questions Should I buy or sell Mereo BioPharma Group stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MREO shares. View MREO analyst ratings or view top-rated stocks. What is Mereo BioPharma Group's stock price target for 2024? 2 Wall Street analysts have issued 12 month price objectives for Mereo BioPharma Group's stock. Their MREO share price targets range from $6.00 to $7.00. On average, they anticipate the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 102.5% from the stock's current price. View analysts price targets for MREO or view top-rated stocks among Wall Street analysts. How have MREO shares performed in 2024? Mereo BioPharma Group's stock was trading at $2.31 at the start of the year. Since then, MREO shares have increased by 39.0% and is now trading at $3.21. View the best growth stocks for 2024 here. When is Mereo BioPharma Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our MREO earnings forecast. How were Mereo BioPharma Group's earnings last quarter? Mereo BioPharma Group plc (NASDAQ:MREO) posted its earnings results on Thursday, September, 7th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). What ETFs hold Mereo BioPharma Group's stock? ETFs with the largest weight of Mereo BioPharma Group (NASDAQ:MREO) stock in their portfolio include Tema Oncology ETF (CANC) and Tema Cardiovascular and Metabolics ETF (HRTS). What other stocks do shareholders of Mereo BioPharma Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include VBI Vaccines (VBIV), Pfizer (PFE), Otonomy (OTIC), OpGen (OPGN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Vaxart (VXRT), Aduro Biotech (ADRO) and Affimed (afmd). When did Mereo BioPharma Group IPO? Mereo BioPharma Group (MREO) raised $49 million in an initial public offering (IPO) on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers. Who are Mereo BioPharma Group's major shareholders? Mereo BioPharma Group's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Monaco Asset Management SAM (0.32%), BNP Paribas Financial Markets (0.01%), SG Americas Securities LLC (0.01%) and Advisors Preferred LLC (0.01%). How do I buy shares of Mereo BioPharma Group? Shares of MREO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MREO) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
